Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

May 07, 2024

SELL
$3.85 - $6.59 $148,610 - $254,374
-38,600 Reduced 20.71%
147,800 $585,000
Q4 2023

Feb 14, 2024

BUY
$3.95 - $6.58 $108,230 - $180,292
27,400 Added 17.23%
186,400 $926,000
Q3 2023

Nov 14, 2023

BUY
$4.8 - $6.4 $118,080 - $157,440
24,600 Added 18.3%
159,000 $802,000
Q2 2023

Aug 11, 2023

BUY
$5.03 - $9.9 $422,017 - $830,610
83,900 Added 166.14%
134,400 $676,000
Q1 2023

May 16, 2023

SELL
$5.68 - $11.99 $399,304 - $842,897
-70,300 Reduced 58.2%
50,500 $310,000
Q4 2022

Feb 14, 2023

BUY
$4.92 - $13.2 $285,852 - $766,920
58,100 Added 92.66%
120,800 $1.59 Million
Q3 2022

Nov 14, 2022

SELL
$3.04 - $5.79 $179,360 - $341,610
-59,000 Reduced 48.48%
62,700 $186,000

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $85.7M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.